Table 1.
Baseline characteristics and clinical presentations of different groups
| PPNAD | BMAH | ADA | P-value | |
|---|---|---|---|---|
| N | 25 | 27 | 84 | |
| Male | 8 $ | 13 # | 6 | 0.000 |
| Female | 17 $ | 14 # | 78 | 0.000 |
| Age of diagnosis (years) | 23 ± 11 | 50 ± 10 | 34 ± 9 | 0.58 |
| Hypertension | 19 of 25 (76.0%)* | 27 of 27 (100%) # | 49 of 61 (80.3%) | 0.03 |
| Osteoporosis or osteopenia | 18 of 23 (78.3%) | 20 of 27 (74.1%) | 24 of 50 (48.0%) $ | 0.015 |
| Hypokalemia | 3 of 25 (12.0%)* | 14 of 27 (51.9%) | 28 of 84 (33.3%) | 0.009 |
| IGT or DM | 14 of 25 (56.0%) | 18 of 27 (66.7%) | 39 of 80 (48.8%) | 0.263 |
PPNAD primary pigmented nodular adrenocortical disease, BMAH bilateral macronodular adrenal hyperplasia, ADA adrenocortical adenoma, IGT impaired glucose tolerance, DM diabetes mellitus
* PPNAD vs. BMAH, P < 0.017; # BMAH vs. ADA, P < 0.017; $ PPNAD vs. ADA P < 0.017